Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine for COVID-19 pneumonia
ChiCTR2000029740Phase 4Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of hydroxychloroquine in coronavirus pneumonia (2 arms), sponsored by Peking University First Hospital. Primary endpoints: oxygen index at 4 weeks, maximum respiratory rate per week at 4 weeks and 6 more. Started Feb 2020; status: recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on ChiCTR2000029740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029740.